Log In
Print this Print this

Lyxumia, lixisenatide (AVE0010, ZP10)

  Manage Alerts
Collapse Summary General Information
Company Zealand Pharma A/S
DescriptionGlucagon-like peptide-1 receptor (GLP-1R; GLP1R) agonist
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat predominantly obese Type II diabetics who experienced poor control on basal insulin with or without oral anti-diabetics for >6 months; Treat Type II diabetes
Regulatory Designation U.S. - Undisclosed Review (Treat Type II diabetes)
Partner Sanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today